OTCMKTS:BIOVF Swedish Orphan Biovitrum (BIOVF) Stock Price, News & Analysis $30.75 +1.78 (+6.14%) As of 08/22/2025 10:26 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestBuy This Stock About Swedish Orphan Biovitrum Stock (OTCMKTS:BIOVF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BIOVF alerts:Sign Up Key Stats Today's Range$30.00▼$30.7550-Day Range$27.06▼$31.9952-Week Range$25.80▼$32.25Volume243 shsAverage Volume39 shsMarket Capitalization$10.95 billionP/E Ratio25.84Dividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company Overview Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden. Read More Receive BIOVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOVF Stock News HeadlinesSobi has completed issues of class C sharesAugust 21 at 7:54 AM | finance.yahoo.comSwedish Orphan Biovitrum AB (BIOVF) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...July 19, 2025 | finance.yahoo.comTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.August 24 at 2:00 AM | American Alternative (Ad)Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2025 Earnings Call TranscriptJuly 16, 2025 | seekingalpha.comSwedish Orphan Biovitrum AB Non-GAAP EPS of SEK 2.36, revenue of SEK 6.17B; reaffirms FY25 outlookJuly 16, 2025 | seekingalpha.comSwedish Orphan Biovitrum AB (BIOVF) Reports Strong Q2 Revenue GrowthJuly 16, 2025 | gurufocus.comSobi Board Approves Share Repurchase for Incentive ProgramJuly 15, 2025 | tipranks.comSobi and Apellis Amend Royalty Agreement for AspaveliJuly 1, 2025 | tipranks.comSee More Headlines BIOVF Stock Analysis - Frequently Asked Questions How have BIOVF shares performed this year? Swedish Orphan Biovitrum's stock was trading at $27.66 at the start of the year. Since then, BIOVF stock has increased by 11.2% and is now trading at $30.75. How were Swedish Orphan Biovitrum's earnings last quarter? Swedish Orphan Biovitrum (OTCMKTS:BIOVF) announced its quarterly earnings data on Wednesday, July, 16th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.06. The company earned $649.61 million during the quarter, compared to analyst estimates of $644.68 million. Swedish Orphan Biovitrum had a net margin of 16.05% and a trailing twelve-month return on equity of 11.67%. How do I buy shares of Swedish Orphan Biovitrum? Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/16/2025Today8/24/2025Next Earnings (Estimated)10/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolOTCMKTS:BIOVF CIKN/A Webwww.sobi.com Phone(468) 697-2000FaxN/AEmployees1,937Year Founded2001Profitability EPS (Trailing Twelve Months)$1.19 Trailing P/E Ratio25.84 Forward P/E RatioN/A P/E GrowthN/ANet Income$367.52 million Net Margins16.05% Pretax Margin18.72% Return on Equity11.67% Return on Assets6.34% Debt Debt-to-Equity Ratio0.22 Current Ratio1.00 Quick Ratio0.66 Sales & Book Value Annual Sales$2.46 billion Price / Sales4.45 Cash Flow$2.05 per share Price / Cash Flow14.99 Book Value$11.36 per share Price / Book2.71Miscellaneous Outstanding Shares356,000,000Free FloatN/AMarket Cap$10.95 billion OptionableNot Optionable Beta0.46 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (OTCMKTS:BIOVF) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Swedish Orphan Biovitrum Please log in to your account or sign up in order to add this asset to your watchlist. Share Swedish Orphan Biovitrum With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.